Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation

Giuseppe Bruschi, Federico De Marco, Thomas Modine, Luca Botta, Paola Colombo, Silvia Mauri, Aldo Cannata, Pasquale Fratto, Silvio Klugmann

Research output: Contribution to journalArticle

Abstract

Transcatheter aortic valve implantation (TAVI) is used to treat elderly patients with severe aortic stenosis who are considered extremely high-risk surgical candidates. The safety and effectiveness of TAVI have been demonstrated in numerous studies. The self-expanding CoreValve bioprosthesis (Medtronic Inc., Minneapolis, MN, USA) was the first transcatheter aortic valve to be granted the Conformité Européene (CE) mark in May 2007 for retrograde transfemoral implantation. However, TAVI patients are also often affected by severe iliofemoral arteriopathy. In these patients, the retrograde transfemoral approach carries a high risk of vascular injury, making this approach unusable. Alternative arterial access sites, such as the subclavian artery, the ascending aorta, and the carotid artery, have been used for retrograde implantation of the CoreValve bioprosthesis. In the present report, we present the procedural considerations, risks, and benefits of the different types of arterial access used to implant the CoreValve bioprosthesis.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalExpert Review of Medical Devices
Volume12
Issue number3
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Bioprosthesis
Subclavian Artery
Vascular System Injuries
Aortic Valve Stenosis
Aortic Valve
Carotid Arteries
Aorta
Safety
Transcatheter Aortic Valve Replacement

Keywords

  • Aortic stenosis
  • Catheter-based valve intervention
  • CoreValve
  • Structural heart disease
  • transcatheter technique

ASJC Scopus subject areas

  • Surgery
  • Biomedical Engineering
  • Medicine(all)

Cite this

Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation. / Bruschi, Giuseppe; De Marco, Federico; Modine, Thomas; Botta, Luca; Colombo, Paola; Mauri, Silvia; Cannata, Aldo; Fratto, Pasquale; Klugmann, Silvio.

In: Expert Review of Medical Devices, Vol. 12, No. 3, 01.05.2015, p. 279-286.

Research output: Contribution to journalArticle

Bruschi, G, De Marco, F, Modine, T, Botta, L, Colombo, P, Mauri, S, Cannata, A, Fratto, P & Klugmann, S 2015, 'Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation', Expert Review of Medical Devices, vol. 12, no. 3, pp. 279-286. https://doi.org/10.1586/17434440.2015.1005605
Bruschi, Giuseppe ; De Marco, Federico ; Modine, Thomas ; Botta, Luca ; Colombo, Paola ; Mauri, Silvia ; Cannata, Aldo ; Fratto, Pasquale ; Klugmann, Silvio. / Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation. In: Expert Review of Medical Devices. 2015 ; Vol. 12, No. 3. pp. 279-286.
@article{5b20167d70fd4add8938cfab9f3f725a,
title = "Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation",
abstract = "Transcatheter aortic valve implantation (TAVI) is used to treat elderly patients with severe aortic stenosis who are considered extremely high-risk surgical candidates. The safety and effectiveness of TAVI have been demonstrated in numerous studies. The self-expanding CoreValve bioprosthesis (Medtronic Inc., Minneapolis, MN, USA) was the first transcatheter aortic valve to be granted the Conformit{\'e} Europ{\'e}ene (CE) mark in May 2007 for retrograde transfemoral implantation. However, TAVI patients are also often affected by severe iliofemoral arteriopathy. In these patients, the retrograde transfemoral approach carries a high risk of vascular injury, making this approach unusable. Alternative arterial access sites, such as the subclavian artery, the ascending aorta, and the carotid artery, have been used for retrograde implantation of the CoreValve bioprosthesis. In the present report, we present the procedural considerations, risks, and benefits of the different types of arterial access used to implant the CoreValve bioprosthesis.",
keywords = "Aortic stenosis, Catheter-based valve intervention, CoreValve, Structural heart disease, transcatheter technique",
author = "Giuseppe Bruschi and {De Marco}, Federico and Thomas Modine and Luca Botta and Paola Colombo and Silvia Mauri and Aldo Cannata and Pasquale Fratto and Silvio Klugmann",
year = "2015",
month = "5",
day = "1",
doi = "10.1586/17434440.2015.1005605",
language = "English",
volume = "12",
pages = "279--286",
journal = "Expert Review of Medical Devices",
issn = "1743-4440",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Alternative transarterial access for CoreValve transcatheter aortic bioprosthesis implantation

AU - Bruschi, Giuseppe

AU - De Marco, Federico

AU - Modine, Thomas

AU - Botta, Luca

AU - Colombo, Paola

AU - Mauri, Silvia

AU - Cannata, Aldo

AU - Fratto, Pasquale

AU - Klugmann, Silvio

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Transcatheter aortic valve implantation (TAVI) is used to treat elderly patients with severe aortic stenosis who are considered extremely high-risk surgical candidates. The safety and effectiveness of TAVI have been demonstrated in numerous studies. The self-expanding CoreValve bioprosthesis (Medtronic Inc., Minneapolis, MN, USA) was the first transcatheter aortic valve to be granted the Conformité Européene (CE) mark in May 2007 for retrograde transfemoral implantation. However, TAVI patients are also often affected by severe iliofemoral arteriopathy. In these patients, the retrograde transfemoral approach carries a high risk of vascular injury, making this approach unusable. Alternative arterial access sites, such as the subclavian artery, the ascending aorta, and the carotid artery, have been used for retrograde implantation of the CoreValve bioprosthesis. In the present report, we present the procedural considerations, risks, and benefits of the different types of arterial access used to implant the CoreValve bioprosthesis.

AB - Transcatheter aortic valve implantation (TAVI) is used to treat elderly patients with severe aortic stenosis who are considered extremely high-risk surgical candidates. The safety and effectiveness of TAVI have been demonstrated in numerous studies. The self-expanding CoreValve bioprosthesis (Medtronic Inc., Minneapolis, MN, USA) was the first transcatheter aortic valve to be granted the Conformité Européene (CE) mark in May 2007 for retrograde transfemoral implantation. However, TAVI patients are also often affected by severe iliofemoral arteriopathy. In these patients, the retrograde transfemoral approach carries a high risk of vascular injury, making this approach unusable. Alternative arterial access sites, such as the subclavian artery, the ascending aorta, and the carotid artery, have been used for retrograde implantation of the CoreValve bioprosthesis. In the present report, we present the procedural considerations, risks, and benefits of the different types of arterial access used to implant the CoreValve bioprosthesis.

KW - Aortic stenosis

KW - Catheter-based valve intervention

KW - CoreValve

KW - Structural heart disease

KW - transcatheter technique

UR - http://www.scopus.com/inward/record.url?scp=84927659752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927659752&partnerID=8YFLogxK

U2 - 10.1586/17434440.2015.1005605

DO - 10.1586/17434440.2015.1005605

M3 - Article

C2 - 25672856

AN - SCOPUS:84927659752

VL - 12

SP - 279

EP - 286

JO - Expert Review of Medical Devices

JF - Expert Review of Medical Devices

SN - 1743-4440

IS - 3

ER -